Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026

PRECISION BIOSCIENCES INC

FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.
Cash $116.7M at Dec 31, 2023; recent $40M public offering and CAR T licensing deals add ~$50M.
Completed licensing deals with Imugene, TG Therapeutics, and Caribou; total upfront/near-term ~$50M.
PBGENE-HBV IND/CTA submission planned in 2024; PBGENE-PMM submission in 2025.
Net loss per diluted share $(15.96) vs $(38.10) in FY 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported financial results for quarter and fiscal year ended December 31, 2023.

Period: quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-24-036816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.